Product Description
ASP3082 is a potential new treatment for people with certain solid tumors. Before ASP3082 is available as a treatment, the researchers need to understand how it is processed by and acts upon the body. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05382559)
Mechanisms of Action: KRAS G12D Degrader
Novel Mechanism: Yes
Modality: N/A
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: France, Japan, Korea, Spain, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Body Temperature Changes|Hypertension|Non-Small-Cell Lung Cancer|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 3082-CL-0101 | P1 |
Recruiting |
Hypertension|Non-Small-Cell Lung Cancer|Body Temperature Changes|Small Cell Lung Cancer |
2026-10-31 |
|
| jRCT2031220738 | P1 |
Recruiting |
Small Cell Lung Cancer|Non-Small-Cell Lung Cancer |
2026-06-30 |